Phase 1/2Completed
An Investigational Immuno-therapy Study Of Nivolumab In Combination With Trametinib With Or Without Ipilimumab In Participants With Previously Treated Cancer of the Colon or Rectum That Has Spread (CheckMate 9N9)
A Study Of Nivolumab In Combination With Trametinib With Or Without Ipilimumab In Participants With Previously Treated Metastatic Colorectal Cancers
- Sponsor
- Bristol-Myers Squibb (Industry)
- Enrollment
- 325 enrolled
- Conditions
- Colorectal Cancer; Colorectal Tumors; Colorectal Carcinoma; Colorectal Neoplasm
- Interventions
- Nivolumab; Trametinib; Ipilimumab; Regorafenib
- Ages
- adults, older adults
- Registry
- NCT03377361, EUCTR2017-001830-24
Full record on ClinicalTrials.gov
From the registry
The purpose of this study is to investigate treatment with nivolumab in combination with trametinib with or without ipilimumab in participants with previously treated cancer of the colon or rectum that has spread.
Primary outcomes
- Dose Limiting Toxicities in Part 1 and Part 1A
- Safety Related Events in Part 1 and Part 1 A
- Clinical Laboratory Abnormalities in Part 1 and Part 1A: Specific Thyroid Tests
- Clinical Laboratory Abnormalities in Part 1 and Part 1A: Specific Liver Tests
History
Results first posted
Last registry update
Primary completion
Started
Registered